Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (131-140 of 323) with videos related to

Pageof 33
Sort By:
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 28, 2024
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA DamageYu-Tzu Tai, Gerrard Teoh, Boris Lin, et al.
Blood|May 12, 2005
A SCID-hu in vivo model of human Waldenström macroglobulinemiaPierfrancesco Tassone, Paola Neri, Jeffery L Kutok, et al.
British Journal of Haematology|February 16, 2017
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panelShirley D'Sa, Marie José Kersten, Jorge J Castillo, et al.
Oncogene|August 13, 2002
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsConstantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, et al.
Leukemia|February 3, 2026
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterationsAlberto Guijosa, Nicholas Tsakmaklis, Margaret Kobs, et al.
Oncogene|November 11, 2024
Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsConstantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, et al.
Open Forum Infectious Diseases|May 2, 2022
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE StudySteven E Coutre, Christopher Barnett, Olayemi Osiyemi, et al.
Seminars in Oncology|April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRobert A Kyle, Steven P Treon, Raymond Alexanian, et al.
Pageof 33

Showing results (131-140 of 323) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 28, 2024
Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA DamageYu-Tzu Tai, Gerrard Teoh, Boris Lin, et al.
Blood|May 12, 2005
A SCID-hu in vivo model of human Waldenström macroglobulinemiaPierfrancesco Tassone, Paola Neri, Jeffery L Kutok, et al.
British Journal of Haematology|February 16, 2017
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panelShirley D'Sa, Marie José Kersten, Jorge J Castillo, et al.
Oncogene|August 13, 2002
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsConstantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, et al.
Leukemia|February 3, 2026
Off-trial outcomes of zanubrutinib in Waldenström macroglobulinemia: the prognostic impact of CXCR4 and TP53 alterationsAlberto Guijosa, Nicholas Tsakmaklis, Margaret Kobs, et al.
Oncogene|November 11, 2024
Editorial Expression of Concern: Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implicationsConstantine S Mitsiades, Nicholas Mitsiades, Vassiliki Poulaki, et al.
Open Forum Infectious Diseases|May 2, 2022
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE StudySteven E Coutre, Christopher Barnett, Olayemi Osiyemi, et al.
Seminars in Oncology|April 30, 2003
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRobert A Kyle, Steven P Treon, Raymond Alexanian, et al.
Pageof 33